Lung Cancer: A Wily Genetic Opponent Peggy P. Hsu, Alice T. Shaw Cell Volume 169, Issue 5, Pages 777-779 (May 2017) DOI: 10.1016/j.cell.2017.05.001 Copyright © 2017 Elsevier Inc. Terms and Conditions
Figure 1 Strategies for Countering ITH and Evolution in the Clinic At time of diagnosis (A), ITH exists, allowing for tumor evolution both in the absence (B) and presence (D) of treatment. Early detection, targeting truncal mutations (C), or inhibiting underlying mechanisms by which heterogeneity is generated (E) are approaches to address ITH. Rationally sequencing therapies might allow us to predict and actively shape tumor evolution (F). Cell 2017 169, 777-779DOI: (10.1016/j.cell.2017.05.001) Copyright © 2017 Elsevier Inc. Terms and Conditions